Opioid-induced constipation in intensive care patients: relief in sight?

Daniel Chappell, Markus Rehm, Peter Conzen, Daniel Chappell, Markus Rehm, Peter Conzen

Abstract

Constipation is the most common gastrointestinal complication associated with opioid therapy in chronic pain patients, and also frequently occurs in sedated intensive care unit patients. Conventional therapy may not provide sufficient relief from constipation, which can be severe enough to limit opioid use or the dose. In a recent study on terminally ill patients suffering from laxative-resistant opioid-induced constipation, Thomas and colleagues demonstrated subcutaneous methylnaltrexone to rapidly induce defecation. This appealing result might also have favourable prospects for intensive care patients, as their outcome is often codetermined by recovery of bowel functioning.

References

    1. Mutlu GM, Mutlu EA, Factor P. GI complications in patients receiving mechanical ventilation. Chest. 2001;119:1222–1241. doi: 10.1378/chest.119.4.1222.
    1. Nguyen NQ, Ng MP, Chapman M, Fraser RJ, Holloway RH. The impact of admission diagnosis on gastric emptying in critically ill patients. Crit Care. 2007;11:R16. doi: 10.1186/cc5685.
    1. Reintam A, Parm P, Redlich U, Tooding LM, Starkopf J, Köhler F, Spies C, Kern H. Gastrointestinal failure in intensive care: a retrospective clinical study in three different intensive care units in Germany and Estonia. BMC Gastroenterol. 2006;6:19. doi: 10.1186/1471-230X-6-19.
    1. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008;35:103–113. doi: 10.1016/j.jpainsymman.2007.01.017.
    1. Mostafa SM, Bhandari S, Ritchie G, Gratton N, Wenstone R. Constipation and its implications in the critically ill patient. Br J Anaesth. 2003;91:815–819. doi: 10.1093/bja/aeg275.
    1. Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, Stambler N, Kremer AB, Israel RJ. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358:2332–2343. doi: 10.1056/NEJMoa0707377.
    1. Yuan CS, Foss JF. Oral methylnaltrexone for opioid-induced constipation. JAMA. 2000;284:1383–1384. doi: 10.1001/jama.284.11.1383.
    1. Yuan CS, Doshan H, Charney MR, O'Connor M, Karrison T, Maleckar SA, Israel RJ, Moss J. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol. 2005;45:538–546. doi: 10.1177/0091270004273491.
    1. Berde C, Nurko S. Opioid side effects – mechanism-based therapy. N Engl J Med. 2008;358:2400–2402. doi: 10.1056/NEJMe0801783.
    1. Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage. 2002;23:48–53. doi: 10.1016/S0885-3924(01)00369-4.
    1. Liu SS, Hodgson PS, Carpenter RL, Fricke JR., Jr ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther. 2001;69:66–71. doi: 10.1067/mcp.2001.112680.
    1. Spoel JI van der, Schultz MJ, Voort PH van der, de Jonge E. Influence of severity of illness, medication and selective decontamination on defecation. Intensive Care Med. 2006;32:875–880. doi: 10.1007/s00134-006-0175-9.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi